Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis.

OBJECTIVE To determine whether anti-apolipoprotein A-1 (anti-Apo A-1) IgG are associated with major cardiovascular events in patients with rheumatoid arthritis (RA). METHODS We determined anti-Apo A-1 IgG levels and the concentrations of cytokines, oxidized low-density lipoprotein (LDL), and matrix metalloproteinase 1 (MMP-1) MMP-2, MMP-3, and MMP-9 in sera from 133 patients with RA who did not have cardiovascular disease at baseline, all of whom were longitudinally followed up over a median period of 9 years. A major cardiovascular event was defined as a fatal or nonfatal stroke or acute coronary syndrome. The proinflammatory effects of anti-Apo A-1 IgG were assessed on human macrophages in vitro. RESULTS During followup, the overall incidence of major cardiovascular events was 15% (20 of 133 patients). At baseline, anti-Apo A-1 IgG positivity was 17% and was associated with a higher incidence of major cardiovascular events (adjusted hazard ratio 4.2, 95% confidence interval 1.5-12.1). Patients who experienced a subsequent major cardiovascular event had higher circulating levels of anti-Apo A-1 IgG at baseline compared with those who did not have a major cardiovascular event. Receiver operating curve analysis showed that anti-Apo A-1 IgG was the strongest of all tested biomarkers for the prediction of a subsequent major cardiovascular event, with an area under the curve value of 0.73 (P = 0.0008). At the predefined and previously validated cutoff levels, the specificity and sensitivity of anti-Apo A-1 IgG to predict major cardiovascular events were 50% and 90%, respectively. Anti-Apo A-1 IgG positivity was associated with higher median circulating levels of interleukin-8 (IL-8), oxidized LDL, and MMP-9 and higher proMMP-9 activity as assessed by zymography. On human macrophages, anti-Apo A-1 IgG induced a significant dose-dependent increase in IL-8 and MMP-9 levels and proMMP-9 activity. CONCLUSION Anti-Apo A-1 IgG is an independent predictor of major cardiovascular events in RA, possibly by affecting vulnerability to atherosclerotic plaque.

[1]  L. March,et al.  Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. , 2010, Arthritis and rheumatism.

[2]  F. Mach,et al.  Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. , 2010, European heart journal.

[3]  D. Lawlor,et al.  Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women , 2010, Atherosclerosis.

[4]  H. Arnesen,et al.  The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina. , 2009, Thrombosis research.

[5]  L. Stojanovich Autonomic dysfunction in autoimmune rheumatic disease. , 2009, Autoimmunity reviews.

[6]  M. Kaplan Management of cardiovascular disease risk in chronic inflammatory disorders , 2009, Nature Reviews Rheumatology.

[7]  S. Hazen,et al.  Myeloperoxidase, modified lipoproteins, and atherogenesis Published, JLR Papers in Press, December 16, 2008. , 2009, Journal of Lipid Research.

[8]  F. Mach,et al.  Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. , 2008, Rheumatology.

[9]  Arthur S Slutsky,et al.  Human neutrophil peptides: a novel potential mediator of inflammatory cardiovascular diseases. , 2008, American journal of physiology. Heart and circulatory physiology.

[10]  G. Tsay,et al.  Elevated circulatory MMP-2 and MMP-9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus. , 2008, Clinical biochemistry.

[11]  J. Chevrolet,et al.  Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome. , 2008, Clinical science.

[12]  C. Turesson,et al.  Cardiovascular co-morbidity in rheumatic diseases , 2008, Vascular health and risk management.

[13]  S. Sela,et al.  Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients. , 2008, Atherosclerosis.

[14]  K. Node,et al.  Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease. , 2008, International journal of cardiology.

[15]  C. Vahl,et al.  Subendothelial infiltration of neutrophil granulocytes and liberation of matrix-destabilizing enzymes in an experimental model of human neo-intima , 2008, Thrombosis and Haemostasis.

[16]  D. O'leary,et al.  Acceleration of atherosclerosis during the course of rheumatoid arthritis. , 2007, Atherosclerosis.

[17]  P. Heeringa,et al.  Accumulation of Myeloperoxidase-Positive Neutrophils in Atherosclerotic Lesions in LDLR−/− Mice , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[18]  A. Newby Metalloproteinases and vulnerable atherosclerotic plaques. , 2007, Trends in cardiovascular medicine.

[19]  C. Cooper,et al.  The autoantibody rheumatoid factor may be an independent risk factor for ischaemic heart disease in men , 2007, Heart.

[20]  A. Becker,et al.  Elevated plasma levels of oxidized low-density lipoprotein relate to the presence of angiographically detected complex and thrombotic coronary artery lesion morphology in patients with unstable angina. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[21]  T. Ueland,et al.  Chemokines in cardiovascular risk prediction , 2007, Thrombosis and Haemostasis.

[22]  Leong L Ng,et al.  Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. , 2007, European heart journal.

[23]  E. Kruithof,et al.  The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. , 2007, Blood.

[24]  T. Pincus,et al.  Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis , 2006, Arthritis research & therapy.

[25]  Marie-Louise Öhman,et al.  Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[26]  Maya Ram,et al.  Matrix Metalloproteinase-9 and Autoimmune Diseases , 2006, Journal of Clinical Immunology.

[27]  C. Vassanelli,et al.  Plasma levels of oxidized-low-density lipoproteins are higher in patients with unstable angina and correlated with angiographic coronary complex plaques. , 2006, Atherosclerosis.

[28]  H. Quan,et al.  Multiplicity adjustment for multiple endpoints in clinical trials with multiple doses of an active treatment , 2005, Statistics in medicine.

[29]  G. Hansson Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.

[30]  J. Dayer,et al.  Presence of autoantibodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease. , 2004, Journal of autoimmunity.

[31]  Imran Awan,et al.  Leukocyte count and coronary heart disease: implications for risk assessment. , 2004, Journal of the American College of Cardiology.

[32]  R. Peters,et al.  IL-8 Plasma Concentrations and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[33]  S. Y. Park,et al.  Serum oxidized low-density lipoproteins in rheumatoid arthritis , 2004, Rheumatology International.

[34]  F. Breedveld,et al.  Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis , 2003, Annals of the rheumatic diseases.

[35]  C. Brunelli,et al.  Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure , 2003, European journal of clinical investigation.

[36]  G. Hughes,et al.  Oxidized low-density lipoprotein as a risk factor of thrombosis in antiphospholipid syndrome , 2003, Lupus.

[37]  JoAnn E. Manson,et al.  Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Arthritis , 2003, Circulation.

[38]  M. Cutolo,et al.  Synovial fluid from patients with rheumatoid arthritis inhibits neutrophil apoptosis: role of adenosine and proinflammatory cytokines. , 2002, Rheumatology.

[39]  A. Hamsten,et al.  Risk Factors for Cardiovascular Disease in Systemic Lupus Erythematosus , 2001, Circulation.

[40]  F. Van de Werf,et al.  Circulating Oxidized LDL Is a Useful Marker for Identifying Patients With Coronary Artery Disease , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[41]  N. Hyka,et al.  Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. , 2001, Blood.

[42]  W A Wilson,et al.  International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. , 1999, Arthritis and rheumatism.

[43]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[44]  F. Arnett Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[45]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[46]  M. Marmot,et al.  Alcohol and coronary heart disease. , 1984, International journal of epidemiology.

[47]  Victoria M Hitchins,et al.  Bacterial endotoxin testing: a report on the methods, background, data, and regulatory history of extraction recovery efficiency. , 2004, Biomedical instrumentation & technology.

[48]  F. Wolfe,et al.  Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. , 2003, The Journal of rheumatology.

[49]  A. Naylor,et al.  Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. , 2000, Stroke.

[50]  B. Deleuran Cytokines in rheumatoid arthritis. Localization in arthritic joint tissue and regulation in vitro. , 1996, Scandinavian journal of rheumatology. Supplement.